Abstract:
A program management structure that includes a plurality of projects, where each project is staffed with a project manager and wherein each project includes a plurality of tasks which can have multiple interdependencies and at least one position reporting up to the project manager. A plurality of organizations is also included, where each organization is provided with a plurality of departments, each of which has a department manager and at least one staffer reporting up to the department manager and filling at least part of the at least one position. Additionally, project exceptions are reported to the project manager and functional exceptions are reported to the functional manager.
Abstract:
The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.
Abstract:
The present invention provides a MAP kinase homologue gene, designated EhHOG, isolated from Eurotium herbariorum, a common fungal species from the extreme hypersaline environment of the Dead Sea, capable of improving tolerance of plants and other organisms to abiotic stresses such as osmotic, heat, dehydration, freezing-thawing, oxidative and salinity stress.
Abstract:
Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.
Abstract:
A shade screen includes a screen fabric, a tightening wire and a reinforcing connector. The reinforcing connector includes a head connecting member and a reinforcing body. The head connecting member has a through connecting slot and a peripheral securing slot. The reinforcing body has a receiving cavity, a first reinforcing groove and a second reinforcing groove formed on two sides of the receiving cavity respectively. The first reinforcing groove and the second reinforcing groove are aligned with two ends of the peripheral securing slot in such a manner that a corner portion of the screen fabric is securely attached in the receiving cavity, while the tightening portion of the tightening wire is arranged to pass through the first reinforcing groove and the second reinforcing groove and fittedly receive in the peripheral securing slot.
Abstract:
Multiple effects with vapor compression distillation apparatus includes a plurality of parallel cylinders or plates for recovery of heat having opposed evaporation and condensation faces for alternately evaporating and condensing. There are forward, backward and parallel feeding method to the upper end of the cylinders or plates for gravity flow along the evaporator face of the cylinders or plates with vapor condensing on the opposite condensation faces. Compressor is included as means for collecting and recovering the condensed product from the system. Alternate embodiments including a solar heat input system and other combined configurations.
Abstract:
Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.
Abstract:
The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.
Abstract:
A method of forming a device is presented. A substrate prepared with an active device region is provided. The active device region includes gate stack layers of a gate stack that includes at least a gate electrode layer over a gate dielectric layer. An implant mask is formed on the substrate with an opening exposing a portion of a top gate stack layers. Ions are implanted through the opening and gate stack layers into the substrate to form a channel well. The substrate is patterned to at least remove portion of a top gate stack layer unprotected by the implant mask.
Abstract:
Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.